| Not Yet Recruiting | Bacterial Decolonization Plus Intraoperative Angiography for Soft Tissue Sarcomas Receiving Preoperative Radio NCT06712433 | Adam Olson | Phase 2 |
| Not Yet Recruiting | Deep Phenotyping Gait Deficits in Orthopedic Manifestations of Pediatric Cancer Patients NCT07502885 | St. Jude Children's Research Hospital | — |
| Not Yet Recruiting | BOLD-100 Plus Doxorubicin in Advanced Soft Tissue Sarcomas NCT07027423 | University Health Network, Toronto | Phase 1 |
| Recruiting | Metformin Hydrochloride in Combination With Standard of Care Systemic Therapy in Previously Untreated Advanced NCT07291297 | Wake Forest University Health Sciences | Phase 2 |
| Recruiting | Short Course of Radiotherapy Prior to Surgery of Soft Tissue Sarcomas NCT07071727 | The Netherlands Cancer Institute | N/A |
| Recruiting | Feasibility of Total Neoadjuvant Treatment With HYPErthermia in Patients With High-risk Extremity and Trunk So NCT06835049 | Swiss Cancer Institute | Phase 2 |
| Recruiting | Preventive Application of Single-use Negative Pressure Wound Therapy (sNPWT) in the Postoperative Course of Ra NCT06941194 | Istituto Oncologico Veneto IRCCS | N/A |
| Recruiting | Sequential Infusion of CD146-Targeted and HER2-Targeted CAR T Cells in Patients With Advanced Sarcomas NCT07066982 | Essen Biotech | Phase 1 / Phase 2 |
| Completed | Descriptive Cohort of French Patients Treated With Carbonetherapy Since October 2010 Outside PHRC-ETOILE NCT06535997 | Hospices Civils de Lyon | — |
| Recruiting | Soft Tissue Sarcoma: Motor Performance, Robotic Rehabilitation, Nutrition, and Quality of Life NCT06873685 | Fondazione Policlinico Universitario Campus Bio-Medico | N/A |
| Active Not Recruiting | Neoadjuvant Intralesional Injection of Talimogene Laherparepvec NCT06660810 | John Rieth | Phase 2 |
| Recruiting | Colorectal Resections in Patients With Retroperitoneal Sarcoma NCT06943612 | Heidelberg University | — |
| Not Yet Recruiting | High Versus Lower Intensity Surveillance Following Resection of Retroperitoneal Sarcoma NCT06480396 | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | Phase 3 |
| Not Yet Recruiting | Safety and Efficacy of Degradable Magnesium Metal Clips in Surgical Margins of Radical Surgery for Malignant B NCT06550765 | Guangdong Provincial People's Hospital | N/A |
| Recruiting | Phase II Clinical Trial of Chidamide Combined With AK112 for Second-line and Advanced Bone and Soft Tissue Sar NCT06637007 | Shanxi Province Cancer Hospital | Phase 2 |
| Active Not Recruiting | A Study to Investigate Efficacy & Safety of Intratumoral INT230-6 Compared to US Standard of Care in Adults Wi NCT06263231 | Intensity Therapeutics, Inc. | Phase 3 |
| Active Not Recruiting | Neoadjuvant ADI-PEG 20 + Ifosfamide + Radiotherapy in Soft Tissue Sarcoma NCT05813327 | Washington University School of Medicine | Phase 1 |
| Recruiting | The Epithelioid Hemangioendothelioma Registry of the European Reference Network on Rare Adult Solid Cancers (E NCT06408441 | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | — |
| Recruiting | Selinexor Plus Gemcitabine in Selected Advanced Soft-tissue Sarcoma (SeliSarc) NCT06114004 | Asociación Europea y Latinoamericana SELNET para la Investigación en Sarcomas | Phase 2 |
| Active Not Recruiting | Pembrolizumab in Combination With Eftilagimod Alpha and Radiotherapy in Neoadjuvant Treatment of Patients With NCT06128863 | Maria Sklodowska-Curie National Research Institute of Oncology | Phase 2 |
| Recruiting | Brachytherapy (Iodine-125 Seeds) and Fluzoparib Combination Therapy for Advanced Unresectable Soft Tissue Sarc NCT05894018 | Fujun Zhang | Phase 2 |
| Recruiting | PARP Inhibition, Stereotactic Body Radiotherapy and Immunotherapy for Metastatic or Advanced Sarcoma (PRIMA) NCT06074692 | Ruijin Hospital | Phase 2 |
| Active Not Recruiting | A Study of Etrumadenant and Zimberelimab in People With Dedifferentiated Liposarcoma NCT05886634 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Completed | Study of DPPG2-TSL-DOX Combined With Hyperthermia in Soft Tissue Sarcoma NCT05858710 | Thermosome GmbH | Phase 1 |
| Recruiting | A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Relapsed/Refractory Bone and Soft Ti NCT05851456 | Shanghai Yunying Medical Technology | EARLY_Phase 1 |
| Active Not Recruiting | In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable a NCT04616248 | University of Southern California | Phase 1 |
| Unknown | Efficacy and Safety Study of Cardunilizumab in Soft Tissue Sarcoma NCT06114173 | Xiangya Hospital of Central South University | EARLY_Phase 1 |
| Active Not Recruiting | A Study of Niraparib in People With Soft Tissue Sarcoma Who Have Changes in Their Tumor DNA NCT05515575 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Active Not Recruiting | Immunotherapy Combined With Radiotherapy for Metastatic Sarcoma NCT05488366 | University of California, Irvine | EARLY_Phase 1 |
| Completed | PSMA Expression and PSMA PET Imaging in Soft Tissue Sarcomas and Urothelial Cell Carcinomas NCT05522257 | Leiden University Medical Center | N/A |
| Recruiting | Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastat NCT05296564 | Hadassah Medical Organization | Phase 1 / Phase 2 |
| Completed | Prehabilitation to Improve Cancer Surgery Outcomes in AYA Patients With Extremity Sarcomas NCT04248959 | University Health Network, Toronto | N/A |
| Unknown | A Phase II Study for 609A in the Treatment of Advanced Undifferentiated Pleomorphic Sarcoma NCT05193214 | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Phase 2 |
| Unknown | A Phase 2 Clinical Study of Evaluation of Recombinant Anti-PD-1 Humanized Monoclonal Antibody Injection (609A) NCT05138146 | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Phase 2 |
| Completed | Preoperative IMRT With Concurrent Apatinib for Localised Extremity or Trunk Sarcoma （SPARE-02） NCT05235100 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Phase 2 |
| Completed | Analysis of the Molecular Profile of the Mixofibrosarcoma of the Extremities NCT04991883 | Istituto Ortopedico Rizzoli | — |
| Recruiting | Endoscopic Surgery in the Treatment of Soft Tissue Sarcoma in Nasal and Paranasal Sinus NCT05614375 | Eye & ENT Hospital of Fudan University | — |
| Completed | Study of Liposomal Annamycin for the Treatment of Subjects with Soft-Tissue Sarcomas (STS) with Pulmonary Meta NCT04887298 | Moleculin Biotech, Inc. | Phase 1 / Phase 2 |
| Completed | The Registry of Oncology Outcomes Associated With Testing and Treatment NCT04028479 | Taproot Health | — |
| Recruiting | A Study of AdAPT-001 in Subjects With Sarcoma and Refractory Solid Tumors NCT04673942 | EpicentRx, Inc. | Phase 2 |
| Recruiting | Pemetrexed, Cisplatin With Soft Tissue Sarcoma NCT04605770 | Yonsei University | Phase 2 |
| Unknown | Camrelizumab Plus Doxorubicin for the First Line Treatment of Adcanced Soft Tissue Sarcoma NCT04910126 | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Phase 2 |
| Recruiting | Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue Sarcoma NCT04577014 | Memorial Sloan Kettering Cancer Center | Phase 1 / Phase 2 |
| Recruiting | Selinexor Plus Gemcitabine in Selected Advanced Soft-tissue Sarcoma and Osteosarcoma NCT04595994 | Grupo Espanol de Investigacion en Sarcomas | Phase 1 |
| Recruiting | Preoperative IMRT With Concurrent Anlotinib for Localised Extremity or Trunk Sarcoma （SPARE-01） NCT05167994 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Phase 2 |
| Unknown | The Combination of Sintilimab and AI (Doxorubicin, ADM/Ifosfamide, IFO) for the First Line Treatment of Select NCT04356872 | Fudan University | Phase 2 |
| Unknown | Anlotinib Combined With Toripalimab in Refractory and Advanced Soft-tissue Sarcoma NCT04172805 | Sun Yat-sen University | Phase 2 |
| Active Not Recruiting | MEK Inhibitor and a PDL1 Inhibitor Patients With Locally Advanced and/or Metastatic Soft Tissue Sarcoma NCT04216953 | Centre Leon Berard | Phase 1 / Phase 2 |
| Terminated | Tranexamic Acid in Radical Resection and Endoprosthetic Reconstruction NCT04347122 | University of Kansas Medical Center | Phase 4 |
| Unknown | Evaluation of Adaptive Radiation Therapy in Pre-operative or Exclusive Radiation Therapy for Limb Soft Tissues NCT03680430 | Institut Paoli-Calmettes | N/A |
| Unknown | Anlotinib Hydrochloride Combined With Epirubicin and Ifosfamide for Soft Tissue Sarcoma Patients NCT03815474 | Liaoning Cancer Hospital & Institute | Phase 2 |
| Recruiting | Neoadjuvant Irradiation of Retroperitoneal Soft Tissue Sarcoma With Ions Retro-Ion NCT04219202 | University Hospital Heidelberg | N/A |
| Withdrawn | Metabolic Characteristics of Sarcoma In Vivo Using HP 13-C Magnetic Resonance Spectroscopic Imaging (MRSI) NCT03759704 | University of Texas Southwestern Medical Center | — |
| Recruiting | GISAR German Interdisciplinary Sarcoma Registry NCT04122872 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | — |
| Unknown | Olaratumab Plus Trabectedin in Advanced Soft-tissue Sarcoma Patients Soft-tissue Sarcoma Patients NCT03985722 | Grupo Espanol de Investigacion en Sarcomas | Phase 1 |
| Active Not Recruiting | Clinical and Biological Activity of an Anti-PD-L1 (Atezolizumab) in Operable Localised Soft Tissue Sarcomas Pa NCT03474094 | Centre Leon Berard | Phase 2 |
| Unknown | Clinical Trial of SP-2577 (Seclidemstat) in Patients With Relapsed or Refractory Ewing or Ewing-related Sarcom NCT03600649 | Salarius Pharmaceuticals, LLC | Phase 1 |
| Terminated | Trabectedin Maintenance Post 1st-line in STS NCT02929394 | European Organisation for Research and Treatment of Cancer - EORTC | Phase 3 |
| Completed | Radiomics for Tumor Grading of Soft Tissue Sarcomas. NCT03798795 | Technical University of Munich | — |
| Terminated | Ph II Nintedanib vs. Ifosfamide in Soft Tissue Sarcoma NCT02808247 | European Organisation for Research and Treatment of Cancer - EORTC | Phase 2 |
| Completed | Low-dose Computer Tomography in Follow-up of Soft Tissue Sarcomas NCT05813808 | Helsinki University Central Hospital | N/A |
| Completed | Transcutaneous Oxygen as a Predictor of Wound Healing Complications in Preoperatively Radiated Soft Tissue Sar NCT02897128 | The Cleveland Clinic | — |
| Completed | Retrospective Study of Trabectedin in Soft Tissue Sarcomas NCT02793050 | Italian Sarcoma Group | — |
| Completed | A Study on Safety and Efficacy in Patients With Soft Tissue Sarcomas NCT03058406 | Eisai Co., Ltd. | — |
| Completed | Doxorubicin With Upfront Dexrazoxane for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma NCT02584309 | Washington University School of Medicine | Phase 2 |
| Withdrawn | Safety Study of BLZ-100 in Adult Subjects With Sarcoma Undergoing Surgery NCT02464332 | Blaze Bioscience Inc. | Phase 1 |
| Completed | A Study to Compare Adjuvant Concurrent Chemoradiation (CCRT) to Adjuvant Radiation Therapy (RT) in Grade 2 and NCT02994264 | Institut de Cancérologie de Lorraine | — |
| Completed | Diffusion Weighted Magnetic Resonance in Imaging Younger Patients With Newly Diagnosed Bone or Soft Tissue Sar NCT02415816 | St. Jude Children's Research Hospital | N/A |
| Withdrawn | Study of Pazopanib Versus Placebo as Maintenance Therapy for Advanced Soft Tissue Sarcoma NCT02367651 | GlaxoSmithKline | Phase 2 |
| Completed | Pazopanib as Front-Line Therapy in Patients With Non-Resectable or Metastatic Soft Tissue Sarcomas Who Are Not NCT02300545 | Washington University School of Medicine | Phase 2 |
| Unknown | Ifosfamide, Doxorubicin and Hypofractionated Radiotherapy in Neoadjuvant Sarcoma Treatment NCT02812654 | AC Camargo Cancer Center | Phase 2 |
| Completed | A Study of Olaratumab and Doxorubicin in Participants With Advanced Soft Tissue Sarcoma NCT02326025 | Eli Lilly and Company | Phase 1 |
| Unknown | Long Term Neurotoxic Effects of Chemotherapy in Survivors of Bone and Soft Tissue Sarcomas. A Retrospective St NCT02309242 | Universitaire Ziekenhuizen KU Leuven | N/A |
| Recruiting | Trabectedin Plus Radiotherapy in Soft Tissue Sarcoma Patients NCT02275286 | Grupo Espanol de Investigacion en Sarcomas | Phase 1 / Phase 2 |
| Unknown | Long Term Morbidity and Quality of Life in Retroperitoneal Sarcomas NCT03480399 | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | — |
| Completed | Study to Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With NCT01962103 | Celgene | Phase 1 / Phase 2 |
| Completed | Individualizing Pazopanib Therapy by exploRing the Role of Early Metabolic responsE and Drug Exposure as a pre NCT01995981 | Radboud University Medical Center | — |
| Completed | (SBRT) and (ART) for Pulmonary Metastases From Soft Tissue Sarcomas NCT01949506 | Medical College of Wisconsin | N/A |
| Terminated | Study of Preoperative Therapy With Pazopanib (Votrient®) to Treat High-risk Soft Tissue Sarcoma NCT01543802 | Heidelberg University | Phase 2 |
| Terminated | Eltrombopag for the Prevention of Chemotherapy Induced Thrombocytopenia NCT01491594 | Duke University | Phase 1 |
| Completed | A Study of Olaratumab in Soft Tissue Sarcoma NCT01185964 | Eli Lilly and Company | Phase 1 / Phase 2 |
| Completed | Combined Modality Treatment of Sarcomas of the Extremities NCT01985295 | The Netherlands Cancer Institute | Phase 1 |
| Completed | Pazopanib Versus Placebo in Patients With Soft Tissue Sarcoma Whose Disease Has Progressed During or Following NCT00753688 | GlaxoSmithKline | Phase 3 |
| Completed | A Study of LY573636-Sodium in the Treatment of Patients With Metastatic Soft Tissue Sarcoma NCT00490451 | Eli Lilly and Company | Phase 2 |
| Terminated | Sunitinib in Certain Subtypes of Soft Tissue Sarcomas NCT00859456 | Columbia University | Phase 2 |
| Completed | BAY-43-9006 in Advanced, Metastatic Soft Tissue Sarcomas NCT00406601 | Istituto Clinico Humanitas | Phase 2 |
| Completed | Chemotherapy Drug Sensitivity Microculture (MiCK) Assay for Apoptosis NCT00243685 | Pierian Biosciences | Phase 2 / Phase 3 |
| Completed | TLC D-99 and Ifosfamide in Metastatic Soft Tissue Sarcoma Patients NCT00289809 | Istituto Clinico Humanitas | Phase 1 / Phase 2 |
| Completed | Pazopanib In Patients With Relapsed Or Refractory Soft Tissue Sarcoma NCT00297258 | GlaxoSmithKline | Phase 2 |
| Completed | Alimta Plus Gemcitabine for Advanced Sarcoma NCT00860015 | Columbia University | Phase 2 |
| Completed | a Multicenter Clinical Trial for the Treatment of Children and Adolescents With Soft Tissue Sarcoma Stage 4 NCT00130858 | Cooperative Weichteilsarkom Study Group | Phase 2 |
| Completed | Study of AP23573/MK-8669 (Ridaforolimus), A Mammalian Target of Rapamycin (mTOR) Inhibitor, in Participants Wi NCT00093080 | Merck Sharp & Dohme LLC | Phase 2 |
| Completed | Everolimus for Treating Pediatric Patients With Recurrent or Refractory Tumors NCT00187174 | St. Jude Children's Research Hospital | Phase 1 |
| Completed | Evaluation of Side Effects and Relative Activity of Two Chemotherapy Regimens in the Treatment Soft Tissue Sar NCT00189137 | University of Michigan Rogel Cancer Center | Phase 2 |
| Unknown | Trofosfamide Versus Adriamycin in Elderly Patients With Soft Tissue Sarcoma (STS) NCT00204568 | University Hospital Schleswig-Holstein | Phase 2 |
| Suspended | Efficacy and Safety Evaluation of Pegamotecan (PEG-camptothecin) in Advanced or Metastatic Soft Tissue Sarcoma NCT00079950 | Enzon Pharmaceuticals, Inc. | Phase 2 |
| Completed | Study Evaluating the Safety and Efficacy of ABT-510 in Subjects With Locally Advanced or Metastatic Soft Tissu NCT00061659 | Abbott | Phase 2 |
| Completed | Study of Gemcitabine and Vinorelbine in Soft Tissue Sarcomas NCT00134641 | Dana-Farber Cancer Institute | Phase 2 |
| Completed | Comparison of Gemcitabine v. Gemcitabine Plus Docetaxel in Unresectable Soft Tissue Sarcoma NCT00142571 | Memorial Sloan Kettering Cancer Center | Phase 3 |
| Completed | Bendamustin Hydrochloride in Patients With Soft Tissue Sarcoma (STS) NCT00204620 | University Hospital Tuebingen | Phase 2 |
| Completed | Neoadjuvant Adriamycin and Ifosfamide Plus High-Dose ICE in Patients With Soft Tissue Sarcoma (STS) NCT00204646 | University Hospital Tuebingen | Phase 2 |
| Available | Catequentinib in Patients Who Have Completed an Advenchen Study (A Compassionate Use Trial) NCT05612191 | Advenchen Laboratories, LLC | — |